Teva/Ivax merger
This article was originally published in The Tan Sheet
Executive Summary
FTC continues to review the consent order signed by Teva Pharmaceutical and Ivax; however, the firms have "no reason to believe that the acceptance will not be forthcoming shortly," the two firms announce Jan. 10. The acquisition of Ivax by Teva is expected close on the third business day following the firms' announcement that FTC has accepted the order, they add. The deal previously was expected to close Jan. 12, and now is anticipated to close "later this month." The acquisition was announced in August (1"The Tan Sheet" Aug. 1, 2005, p. 11)...
You may also be interested in...
Teva Broadens Private Label OTC Offerings With Ivax Acquisition
Teva's planned acquisition of Ivax adds a wide range of private label OTCs to the firm's generic drug portfolio
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.